A variety of approaches to measure the efficacy of PARP inhibitors

Bookmark and Share
Published: 25 Apr 2018
Views: 4639
Dr Elisabetta Leo - AstraZeneca, Cambridge, UK

Dr Leo speaks with ecancer at AACR 2018 about results from a head-to-head comparison of five PARP inhibitors using a novel proteomic assay.

Having compared the approvals, mechanisms and doses of olaparib, veliparib, rucaparib, niraparib and talazoparib, Dr Leo highlights the potential for predicting responses and assessing novel PARP inhibitors.

For more on PARP inhibitors, watch our interview with Dr Mark O’Connor here.